 |
Golden Predator Mining Corp. Announces Termination of Arrangement Agreement with Viva Gold CorpGolden Predator Mining and Viva Gold Corp have mutually agreed to terminate the arrangement agreement dated March 2, 2021 for the proposed acquisition of all of the issued and outstanding shares of Viva Gold by Golden Predator Research, News & Market Data on Golden Predator Mining |
 |
Total Cray Valley and Gevo to further Scale Up Development of Renewable Isoamylene from Fusel OilGevo and Total Cray Valley announced the successful completion of phase 1 of their Joint Development Agreement to upgrade fusel oils into renewable isoamylene Research, News & Market Data on Gevo |
 |
Ocugen announces studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2. Up 17% in early trading.Ocugen, Inc. announced that in a new study, scientists at Indian Council of Medical Research (ICMR)-National Institute of Virology have found that COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2 Research, News & Market Data on Ocugen |
 |
Dyadic to Present at Upcoming EventsDyadic announced that the Company will participate in several upcoming events |
 |
Comtech Awarded $6.2 Million of Additional Funding to Support the U.S. Army’s Blue Force Tracking SystemComtech Telecommunications announced that during its third quarter of fiscal 2021, its Government Solutions segment was awarded $6.2 million of additional funding for Option Period Four of contract GS03Q17DSC0002 Research, News & Market Data on Comtech |
 |
Avivagen Announces Recurring Order for OxC-betaTM LivestockAvivagen announced that Avivagen’s consultant in Mexico has secured their largest purchase amount and longest duration purchase to date Research, News & Market Data on Avivagen |
 |
TAAL Files 2020 Fiscal Year-End Financial Results And Provides Operational Guidance For 2021TAAL announced its financial results and Management Discussion and Analysis for the fiscal year ended December 31, 2020 Research, News & Market Data on TAAL Distributed Information Technologies |
 |
OpRegen® Clinical Data Continues To Demonstrate Improvements In Patients With Dry Amd With Geographic AtrophyLineage Cell Therapeutics announced that updated interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen, were reported at the 2021 Association for Research in Vision and Ophthalmology Annual Meeting Research, News & Market Data on Lineage Cell Therapeutics |
Stay up to date. Follow us:
 |
 |
 |
 |
 |
 |
